Sensors· 2026Q1· Review
Artificial Intelligence for Cardiac Ischemia Detection: A Review of Biosensor, Biomarker, and Imaging Applications
- 0citations
- Q1SCImago
- 2026year
Short summary
Artificial intelligence (AI) can improve cardiac ischemia detection by analyzing data from biosensors, biomarkers, and imaging, addressing limitations of current methods like incomplete signal capture and operator dependence.
AI-generated from the title and abstract; the full text is not read.
Key points
- AI can overcome limitations in cardiac ischemia detection, such as incomplete signal capture and operator dependence.
- AI applications are reviewed across three sensing modalities: ECG (bioelectric), cardiac troponin (biochemical), and cardiac imaging (structural/functional).
- Current evidence primarily comes from retrospective studies assessing diagnostic accuracy, with limited data on clinical workflow, patient outcomes, or cost-effectiveness.
- Future adoption requires prospective multicenter trials, standardized benchmarks, and demonstrated clinical and economic benefits.
AI-generated from the title and abstract; the full text is not read.
Abstract
Ischemic heart disease is the leading cause of global mortality, yet accurate and timely detection remains constrained by incomplete signal capture, noise, operator dependence, and imperfect reference standards. Artificial intelligence (AI) may enhance cardiovascular sensing by extracting latent diagnostic information from routinely acquired signals. This narrative review examines AI-enabled approaches to ischemia detection across three sensing modalities: the electrocardiogram as a bioelectric sensor, cardiac troponin as a biochemical marker, and cardiac imaging technologies (echocardiography, computed tomography, magnetic resonance, and nuclear imaging) as structural and functional sensors. For each modality, we evaluate the sensing pipeline, the reference standards, the endpoint actually measured (from acute coronary occlusion to functional ischemia), and reported performance metrics, separating diagnostic accuracy from effects on clinical workflow, patient outcomes, and cost. We also discuss emerging directions, including foundation models and multimodal fusion, together with translational challenges such as limited prospective validation, regulatory hurdles, and uncertain cost-effectiveness. Most evidence comes from retrospective, frequently single-center studies of diagnostic performance; few studies have measured effects on workflow, and fewer still on patient outcomes or cost. Routine clinical adoption will require prospective multicenter trials, standardized performance benchmarks, and evidence of clinical and economic benefit.
The authors' abstract, as published at the source. Sensors, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Health Information Management
Health Information ManagementHealth Professions